Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

690
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
690
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

957
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
957
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.6K
Vascular Spasm01:16

Vascular Spasm

4.8K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
4.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.0K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.0K
Inflammation01:38

Inflammation

64.3K
Overview
64.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.

Thrombosis research·2024
Same author

Impact of <i>BRAF</i> mutation on aggressiveness and outcomes in adult clonal histiocytosis.

Frontiers in immunology·2023
Same author

[What about the new ACR/EULAR classification criteria for giant cell arteritis?]

La Revue de medecine interne·2023
Same author

La Revue de medecine interne·2023
Same author

[How to apply the EULAR and ACR recommendations for the diagnosis and treatment of giant cell arteritis?]

La Revue de medecine interne·2022
Same author

Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis.

European journal of internal medicine·2021

Related Experiment Video

Updated: Mar 29, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

[Pathogenesis of large vessel vasculitis].

M Samson1, B Bonnotte1

  • 1Service de médecine interne et immunologie clinique, hôpital François Mitterrand, CHU de Dijon, 21000 Dijon, France; Inserm, UMR1098, 25020 Besançon cedex, France; Faculté de médecine, université de Bourgogne, IFR100, Dijon, France.

La Revue De Medecine Interne
|December 2, 2015
PubMed
Summary

Giant cell arteritis (GCA) and Takayasu's arteritis (TA) involve large artery inflammation. Immune cells like T cells and macrophages drive arterial wall damage, leading to GCA and TA complications.

Keywords:
Artérite de TakayasuArtérite à cellules géantesGiant cell arteritisPathogenesisPhysiopathologieTakayasu's arteritis

More Related Videos

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.3K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.4K

Related Experiment Videos

Last Updated: Mar 29, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.3K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.4K

Area of Science:

  • Immunology
  • Vascular Biology
  • Rheumatology

Background:

  • Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are distinct large-artery granulomatous vasculitides.
  • Their pathogenesis involves complex immune responses but remains incompletely understood.
  • Recent advances offer insights into potential new therapeutic strategies.

Purpose of the Study:

  • To elucidate the immunological pathways and cellular players involved in the pathogenesis of GCA and TA.
  • To highlight the shared and distinct features of immune responses in these two vasculitides.

Main Methods:

  • Review of current literature on the immunopathogenesis of GCA and TA.
  • Analysis of cellular and molecular mechanisms driving arterial inflammation and remodeling.

Main Results:

  • Both GCA and TA involve genetic predispositions and share immunological pathways.
  • Infectious agents may trigger dendritic cell activation, leading to adaptive immune cell recruitment (CD4+ Th1/Th17, CD8+ T cells, NK cells).
  • Decreased T regulatory cells (Treg) and involvement of humoral immunity (especially in TA) are noted. Cytokines like IL-17 and IFN-γ drive monocyte differentiation into giant cells, causing arterial damage and symptoms.

Conclusions:

  • Immune dysregulation, involving T cells, macrophages, and cytokines, is central to GCA and TA pathogenesis.
  • Understanding these pathways is crucial for developing targeted therapies for large-artery vasculitis.